Advantageous biological effect, Cesium-131’s short half-life, and new shielded or dynamically modulated sources: Dr. Mark Rivard’s thoughts on brachytherapy from ABS 2018

As a physicist, Dr. Mark Rivard is fascinated by brachytherapy’s ability to provide “conformal, localized” radiotherapy compared to external-beam radiation therapy for treatment of multiple cancer types. He was kind enough to share his thoughts with us in a video interview from the American Brachytherapy Society 2018 Annual Meeting.

When sources are positioned accurately, “No external beam, no proton therapy … none of those other modalities can compete with brachytherapy.”

He particularly appreciates the attributes of high dose rate treatments and the advantageous biological effect of permanent or temporary low dose rate implants that leave little or no trace of their presence for better chances of excellent patient outcomes. 

 

 

Dr. Rivard attributes brachytherapy’s technology resurgence in part to the cesium-131 dose uniformity and more favorable half-life (shorter by a factor of six compared to iodine-125). Thanks to treatment planning advances where clinicians can now account for patient composition and new sources that are shielded or dynamically-modulated, an era of highly-targeted radiotherapy delivery is dawning.

If you have been practicing brachytherapy with anything but cesium-131 or are ready to learn how to add brachytherapy to your cancer treatment arsenal, please contact us to arrange a call or meeting.

My Question is Why?

My Question is Why?

By Dr. Ronald M. BenoitDepartment of Urology, University of Pittsburgh School of Medicine Why would a clinician be hesitant to use Cesium-131 to treat prostate cancer? I would venture to say the likely answer is the data that speaks to its benefits has not yet...

read more
Take Time to Think

Take Time to Think

By Dr. Bernard W. TaylorTexas Oncology - Longview Cancer Center The American Cancer Society’s 2022 Cancer Facts and Figures report estimates that nearly 270,000 men will be diagnosed with prostate cancer this year. This represents nearly 50% more than the number of...

read more
Looking Ahead

Looking Ahead

By CEO Lori Woods This is my first blog post, and it comes during a year that has changed how we communicate, how we work, and virtually every aspect of our lives. COVID-19 has challenged us and changed us. We hope for better days ahead even as we face the reality of...

read more